Blood lead is a predictor of homocysteine levels in a population-based study of older adults

Environmental Health Perspectives

Volumn 113, Issue 1, 2005, Pages 31-35

  Schafer, Jyme H ^a,b   Glass, Thomas A ^a   Bressler, Joseph ^a,b,c   Todd, Andrew C ^d   Schwartz, Brian S ^a,b  

^a JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c KENNEDY KRIEGER INSTITUTE   (United States)

^d MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

Blood lead; Cross sectional study; Homocysteine; Tibia lead

Indexed keywords

CADMIUM 109; HOMOCYSTEINE; LEAD;

ADULT; AFRICAN AMERICAN; AGED; ALCOHOL CONSUMPTION; AMINO ACID BLOOD LEVEL; ARTICLE; BODY MASS; CARDIOVASCULAR SYSTEM; CAUCASIAN; CENTRAL NERVOUS SYSTEM; CONTROLLED STUDY; CORRELATION ANALYSIS; ENZYME INHIBITION; ETHNOLOGY; FEMALE; HEALTH HAZARD; HUMAN; HUMAN EXPERIMENT; LEAD BLOOD LEVEL; LEAD POISONING; LINEAR REGRESSION ANALYSIS; LONGITUDINAL STUDY; MALE; NEGRO; OCCUPATIONAL EXPOSURE; PREDICTION; PREVALENCE; PRIORITY JOURNAL; SMOKING; TIBIA; UNITED STATES; X RAY FLUORESCENCE;

AGED; CARDIOVASCULAR DISEASES; CENTRAL NERVOUS SYSTEM; COGNITION DISORDERS; CROSS-SECTIONAL STUDIES; FEMALE; HOMOCYSTEINE; HUMANS; LEAD; LONGITUDINAL STUDIES; MALE; MIDDLE AGED;

EID: 12744261282     PISSN: 00916765     EISSN: None     Source Type: Journal    
DOI: 10.1289/ehp.7369     Document Type: Article

References (41)

1. ATSDR. 1999. Toxicologic Profile for Lead (Update). Atlanta, GA:Agency for Toxic Substances and Disease Registry.
2. Balbus-Kornfeld JM, Stewart W, Bolla KI, Schwartz BS. 1995. Cumulative exposure to inorganic lead and neurobehavioural test performance in adults: an epidemiological review. Occup Environ Med 52:2-12.
3. Banerjee R, Evande R, Kabil O, Ojha S, Taoka S. 2003. Reaction mechanism and regulation of cystathionine beta-synthase. Biochim Biophys Acta 1647:30-35.
4. Bautista LE, Arenas IA, Penuela A, Martinez LX. 2002. Total plasma homocysteine level and risk of cardiovascular disease: a meta-analysis of prospective cohort studies. J Clin Epidemiol 55:882-887.
5. Canfield RL, Henderson CR Jr, Cory-Slechta DA, Cox C, Jusko TA, Lanphear BP. 2003. Intellectual impairment in children with blood lead concentrations below 10 microg per deciliter. N Engl J Med 348:1517-1526.
6. Carson N, Neill D. 1962. Metabolic abnormalities detected in a survey of mentally backward individuals in Northern Ireland. Arch Dis Childhood 37:505-513.
7. Cheng Y, Schwartz J, Sparrow D, Aro A, Weiss ST, Hu H. 2001. Bone lead and blood lead levels in relation to baseline blood pressure and the prospective development of hypertension: the Normative Aging Study. Am J Epidemiol 153:164-171.
8. Cleveland WS. 1979. Robust locally weighted regression and smoothing scatterplots. J Am Stat Assoc 74:829-836.
9. Dufouil C, Alperovitch A, Ducros V, Tzourio C. 2003. Homocysteine, white matter hyperintensities, and cognition in healthy elderly people. Ann Neurol 53:214-221.
10. Gerritsen T, Vaughn JG, Waisman HA. 1962. The identification of homocysteine in the urine. Biochem Biophys Res Commun 9:493-496.
11. Glenn BS, Stewart WF, Links JM, Todd AC, Schwartz BS. 2003. The longitudinal association of lead with blood pressure. Epidemiology 14:30-36.
12. Goering PL. 1993. Lead-protein interactions as a basis for lead toxicity. Neurotoxicology 14:45-60.
13. Homocysteine Collaboration. 2002. Homocysteine and risk of ischemic heart disease and stroke: a meta-analysis. JAMA 288:2015-2022.
14. Hu H, Rabinowitz M, Smith D. 1998. Bone lead as a biological marker in epidemiologic studies of chronic toxicity: conceptual paradigms. Environ Health Perspect 106:1-8.
15. Jacques PF, Bostom AG, Wilson PW, Rich S, Rosenberg IH, Selhub J. 2001. Determinants of plasma total homocysteine concentration in the Framingham offspring cohort. Am J Clin Nutr 73:613-621.
16. Kopp SJ, Barron JT, Tow JP. 1988. Cardiovascular actions of lead and relationship to hypertension: a review. Environ Health Perspect 78:91-99.
17. Lustberg M, Silbergeld E. 2002. Blood lead levels and mortality. Arch Intern Med 162:2443-2449.
18. Meier M, Janosik M, Kery V, Kraus JP, Burkhard P. 2001. Structure of human cystathionine beta-synthase: a unique pyridoxal 5′-phosphate-dependent heme protein. EMBO J 20:3910-3916.
19. Moller L, Kristensen T. 1992. Blood lead as a cardiovascular risk factor. Am J Epidemiol 136:1091-1100.
20. Mudd S, Finklestein J, Irreverre F, Laster L 1964. Homocystinuria: an enzymatic defect Science 143:1443-1445.
21. Nash D, Lustberg M, Sherwin RW, Rubin RJ, Kaufmann R, Silbergeld E. 2003. Blood lead, blood pressure, and hypertension in perimenopausal and postmenopausal women. JAMA 289:1523-1532.
22. Nriagu JO. 1983. Lead and Lead Poisoning in Antiquity. New York:John Wiley & Sons, 378-415.
23. Pocock S, Shaper A, Ashby D, Delves H, Clayton B. 1988. The relationship between blood lead, blood pressure, stroke, and heart attacks in middle-aged British men. Environ Health Perspect 78:23-30.
24. Prins ND, Den Heijer T, Hofman A, Koudstaal PJ, Jolles J, Clarke R, et al. 2002. Homocysteine and cognitive function in the elderly: the Rotterdam Scan Study. Neurology 59:1375-1380.
25. Ravaglia G, Forti P, Maioli F, Muscari A, Sacchetti L, Arnone G, et al. 2003. Homocysteine and cognitive function in healthy elderly community dwellers in Italy. Am J Clin Nutr 77:668-673.
26. Rodrigo R, Passalacqua W, Araya J, Orellana M, Rivera G. 2003. Implications of oxidative stress and homocysteine in the pathophysiology of essential hypertension. J Cardiovasc Pharmacol 42:453-41.
27. Schwartz BS, Glass T, Bolla K, Glass G, Stewart W, Todd A, et al. 2004. Disparities in cognitive functioning by race/ethnicity in the Baltimore Memory Study. Environ Health Perspect 112:314-420.
28. Schwartz BS, Lee B, Bandeen-Roche K, Stewart W, Bolla K, Links J, et al. In press. Lead dose is associated with longitudinal decline in nourobehavioral test scores in South Korean lead workers. Epidemiology.
29. Schwartz BS, Lee BK, Lee GS, Stewart WF, Lee SS, Hwang KY, et al. 2001. Associations of blood lead, dimercaptosuccinic acid-chelatable lead, and tibia lead with neurobehavioral test scores in South Korean lead workers. Am J Epidemiol 153:453-464.
30. Schwartz BS, Stewart WF, Bolla KI, Simon PD, Bandeen-Roche K, Gordon PB, et al. 2000. Past adult lead exposure is associated with longitudinal decline in cognitive function. Neurology 55:1144-1150.
31. Schwartz BS, Stewart W, Hu H. 2002. Neurobehavioural testing in workers occupationally exposed to lead. Occup Environ Med 59:648-649.
32. Simons TJ. 1995. The affinity of human erythrocyte porphobilinogen synthase for Zn2+ and Pb2+. Eur J Biochem 234:178-183.
33. Todd AC. 2000. Contamination of in vivo bone-lead measurements. Phys Med Biol 45:229-240.
34. Todd AC, Carroll S, Godbold JH, Moshier EL, Khan FA. 2000. Variability in XRF-measured tibia lead levels. Phys Med Biol 45:3737-3748.
35. 109Cd spot source. Basic Life Sci 60:299-302.
36. 109Cd sources: radiation dosimetry studies. Environ Res 57:117-132.
37. Ueland PM, Refsum H, 1989. Plasma homocysteine, a risk factor for vascular disease: plasma levels in health, disease, and drug therapy. J Lab Clin Med 114:473-501.
38. Wald DS, Law M, Morris JK. 2002. Homocysteine and cardiovascular disease: evidence on causality from a meta-analysis. Br Med J 325:1202-1206.
39. Wang H, Jiang X, Yang F, Gaubatz JW, Ma L, Magera MJ, et al. 2003. Hyperhomocysteinemia accelerates atherosclerosis in cystathionine beta-synthase and apolipoprotein E double knock-out mice with and without dietary perturbation. Blood 101:3901-3907.
40. Yap S. 2003. Classical homocystinuria: vascular risk and its prevention. J Inherit Metab Dis 26:259-265.
41. Zeng X, Dai J, Remick DG, Wang X. 2003. Homocysteine mediated expression and secretion of monocyte chemoattractant protein-1 and interleukin-8 in human monocytes. Circ Res 93:311-320.